Price
Frequently asked questions
What is Novavax's market capitalization?
What is the Earnings Per Share (EPS) for Novavax?
What are the analyst ratings and target price for Novavax's stock?
What is Novavax's revenue over the trailing twelve months?
What is the EBITDA for Novavax?
What is the free cash flow of Novavax?
What is the 5-year beta of Novavax's stock?
How many employees does Novavax have, and what sector and industry does it belong to?
What is the free float of Novavax's shares?
Financials
Market Cap
$1.35B5Y beta
2.02EPS (TTM)
-$2.764Free Float
153.08MRevenue (TTM)
$987.67MEBITDA (TTM)
-$240.84MFree Cashflow (TTM)
-$22.47MPricing
Analyst Ratings
The price target is $22.80 and the stock is covered by 6 analysts.
Buy
3
Hold
3
Sell
0
Information
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
1,543
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker